Research progress of clinical application of Zhibitai capsule / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 1912-1916, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-955933
ABSTRACT
Dyslipidemia is the pathological basis of the occurrence and development of atherosclerosis. It is a major independent risk factor for hypertension, coronary heart disease and cerebrovascular disease. Regulating blood lipid level plays an important role in decreasing the incidence of cardio-cerebrovascular disease. Zhibitai capsule, a lipid-regulating Chinese medicine, has the similar effect to statins. We searched animal experiment studies, clinical trials and reviews in China National Knowledge Infrastructure to analyze the application value and advantages of Zhibitai capsule.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS